(Press-News.org) (Edmonton) A team of researchers from the University of Alberta has discovered a new approach to fighting breast and thyroid cancers by targeting an enzyme they say is the culprit for the "vicious cycle" of tumour growth, spread and resistance to treatment.
A team led by University of Alberta biochemistry professor David Brindley found that inhibiting the activity of an enzyme called autotaxin decreases early tumour growth in the breast by up to 70 per cent. It also cuts the spread of the tumour to other parts of the body (metastasis) by a similar margin. Autotaxin is responsible for producing lysophosphatidic acid, a signaling molecule that promotes cancer cell survival, growth and metastasis. It is also linked to resistance to the beneficial effects of chemotherapy and radiotherapy.
"Autotaxin causes a lot of serious problems in the treatment of breast and other cancers. Essentially, the body hijacks this enzyme to help a tumour grow, survive treatment and spread to other areas of the body," said Brindley, senior author of a series of related studies. "By inhibiting it, we found we could block the growth of breast and thyroid tumours and break the cycle of treatment resistance."
Autotaxin is normally involved in wound repair and tissue regeneration. It also drives inflammatory conditions such as colitis, arthritis and cancer. Brindley believes it is this inflammation-associated event that is especially problematic and could fuel breast and thyroid tumour growth.
According to Brindley, a tumour is like a wound that does not heal. The body hijacks autotaxin to help a tumour grow, resist being killed by chemotherapy and radiotherapy, and to spread to other areas of the body. As the tumour grows or is damaged by treatment, it produces more inflammatory mediators, which in turn produce more autotaxin. That then increases the production of more inflammatory mediators. The research team found that it could block the growth of breast and thyroid tumours by breaking the vicious cycle with the autotaxin inhibitor.
Brindley's team--which included co-authors Matthew Benesch, a Vanier Scholar, Killam Laureate, and MD/ PhD candidate in the Faculty of Medicine & Dentistry; Ganesh Venkatraman, an Alberta Innovates-Health Solutions sponsored PhD candidate; Xiaoyun Tang, a Canadian Breast Cancer Foundation-funded postdoctoral fellow; and endocrine surgeon Todd McMullen--used a drug developed by Ono Pharmaceuticals in Japan to inhibit autotaxin activity.
Daily doses of the drug reduced the initial phase of breast tumour growth by 60 to 70 per cent in experimental models. The inhibitor compound also cut tumour metastasis to the lungs by a similar margin. Later tests with a different technique for blocking the effects of lysophosphatidic acid enabled the team to block breast and thyroid tumour growth and spread by up to 80 per cent.
Brindley said his team was surprised when Benesch discovered that autotaxin is not produced by breast cancer cells themselves, but largely by the surrounding breast fat tissue. As the tumour develops and causes inflammation in the breast, the fat tissue produces more autotaxin, aggravating the problem by making the tumour grow more, metastasize and resist further treatment.
"With this drug we are cutting this vicious cycle," he said, explaining that by blocking autotaxin the researchers saw a five-fold reduction in inflammation markers in the blood, and a ten-fold reduction in the breast fat tissue adjacent to the tumour.
The research team is now trying to promote the testing of the compound in human clinical trials in Edmonton--the first autotaxin inhibitor to make it to the clinic after more than 10 years of research. Brindley says that it shows it's not a "pie in the sky" theory but a potential new therapy that could be used in combination with chemotherapy to improve the treatment of cancer patients.
"We've shown that the autotaxin inhibitor has strong therapeutic potential, even though we are at the early stages" he said. "A third of women with breast cancer die from metastasis and many thyroid cancer patients do not respond well to treatment. If we can improve the treatment of these patients, it will be a very big deal."
"This is a very exciting discovery on many levels," said Liz Viccars, CEO, Canadian Breast Cancer Foundation - Prairies/NWT Region. "We are very proud to have supported this work in Dr. Brindley's lab with a CBCF-funded research grant, as well as supporting Dr. Tang's contributions through one of our inaugural Fellowship Grants.
"This discovery is an exceptional demonstration of fundamental basic research potentially leading to the development and implementation of personalized cancer therapies and treatments. The impact of such findings will improve the quality of life and patient care for those dealing with breast and other cancers."
INFORMATION:
The research was published in 2014 in FEBS Letters, the Journal of Lipid Research and two papers in the FASEB Journal. The work was funded by the Canadian Breast Cancer Foundation, Alberta Cancer Foundation, Canadian Institutes of Health Research and Alberta Innovates - Health Solutions.
Link to Dr. Brindley's homepage: http://biochem.med.ualberta.ca/Research/faculty/Professors/Pages/Brindley.aspx
High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two emerging health problems related to the epidemic of childhood obesity. In a recent study, researchers at University of California, San Diego School of Medicine sought to determine the prevalence of high blood pressure in children with NAFLD, which places them at risk for premature cardiovascular disease.
The study, published in the November 24 edition of PLOS ONE, found that children with NAFLD are at substantial risk for high blood pressure, which is commonly undiagnosed.
"As a result of our ...
PRINCETON, N.J.--A team led by researchers from Princeton University, Michigan State University and the Indonesian Institute of Sciences have confirmed the discovery of a new bird species more than 15 years after the elusive animal was first seen on the Indonesian island of Sulawesi.
The newly named Sulawesi streaked flycatcher (Muscicapa sodhii), distinguished by its mottled throat and short wings, was found in the forested lowlands of Sulawesi where it had last been observed. The researchers report in PLOS ONE that the new species is markedly different from other flycatchers ...
November 24, 2014 - Differences in breast size have a significant mental health impact in adolescent girls, affecting self-esteem, emotional well-being, and social functioning, reports the December issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
More than just a "cosmetic issue," breast asymmetry can have negative psychological and emotional effects, according to the study by ASPS Member Surgeon Dr. Brian I. Labow and colleagues of Boston Children's Hospital. They suggest that early intervention ...
November 24, 2014 - For women considering breast reduction surgery, initial evaluation at a shared medical appointment (SMA) provides excellent patient satisfaction in a more efficient clinic visit, reports a study in the December issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Shared medical appointments have additional benefits, including "group learning, peer support, and a sense of solidarity and commonality" among women learning about breast reduction surgery, according to the study ...
Climate change could lengthen the growing season, make soil drier and decrease winter snowpack in the Lake Michigan Basin by the turn of the century, among other hydrological effects.
A new U.S. Geological Survey precipitation and runoff model shows that by 2100, maximum daily temperature in the Lake Michigan Basin could increase by as much as seven degrees Fahrenheit, and the minimum daily temperature by as much as eight degrees. A new USGS report published today summarizes the potential hydrological effects of these increases on the basin through 2099. The tools can ...
Lincoln, Neb., Nov. 24, 2104 -- The improvements in random access memory that have driven many advances of the digital age owe much to the innovative application of physics and chemistry at the atomic scale.
Accordingly, a team led by University of Nebraska-Lincoln researchers has employed a Nobel Prize-winning material and common household chemical to enhance the properties of a component primed for the next generation of high-speed, high-capacity RAM.
The team, which published its findings in the Nov. 24 edition of the journal Nature Communications, engineered and tested ...
Parents who spend their time playing with and talking to their five-month-old baby may wonder whether their child remembers any of it a day later.
Thanks to a new BYU study, we now know that they at least remember the good times.
The study, published in Infant Behavior and Development, shows that babies are more likely to remember something if there is a positive emotion, or affect, that accompanies it.
"People study memory in infants, they study discrimination in emotional affect, but we are the first ones to study how these emotions influence memory," said BYU psychology ...
Honeybee populations are clearly under stress--from the parasitic Varroa mite, insecticides, and a host of other factors--but it's been difficult to pinpoint any one of them as the root cause of devastating and unprecedented losses in honeybee hives. Researchers writing in the Cell Press journal Trends in Parasitology on November 24th say that the problem likely stems from a complex and poorly understood interplay of stresses and their impact on bee immunity and health. It's a situation they suspect might be improved through stress management and better honeybee nutrition.
As ...
MINNEAPOLIS, MN - November 24, 2014 - Nearly all individuals in their late 60s and early 70s -- including 100 percent of men -- now qualify for and should consider starting a statin medication to reduce their risk of cardiovascular disease, under the recently released cholesterol guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA).
That's according to a research letter published today in the 11/20/2014 (JAMA-IM) by Michael D. Miedema, MD, MPH, a research cardiologist at Minneapolis Heart Institute Foundation and cardiologist ...
The immune system is designed to remove things not normally found in the body. Cells undergoing change, e.g. precursors of cancer cells, are therefore normally recognised and removed by the immune system. Unfortunately, the different cancer cells contain mechanisms that block the immune system's ability to recognise them, allowing them to freely continue cancer development.
Certain cancer cells overexpress immunostimulatory molecules in liquid form. Such over-stimulation has a negative impact on the immune system:
"You can say that the stimulating molecules over-activate ...
